Cardiff Oncology, Inc. (CRDF) Misses Q1 EPS by 5c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q1 EPS of ($0.18), $0.05 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $40 thousand versus the consensus estimate of $88.57 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• loanDepot receives NYSE non-compliance notice over stock price
• Lazard Global Total Return fund declares $0.1534 monthly distribution
• Real and RE/MAX Holdings receive court approval for merger